Sanofi (SNY) said Thursday that the National Medical Products in China has approved two of its therapies intended for rate hematologic diseases.
The drugmaker said Qfitlia is approved to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and above, who were diagnosed with hemophilia A or B, with or without inhibitors.
The regulator also approved Cabliv, which is intended to treat acquired or immune-mediated thrombotic thrombocytopenic purpura in patients aged 12 years and up, weighing at least 40 kg.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments